Form 4: Agios Pharmaceuticals Director Jacqualyn Fouse Reports Stock Transactions
SEC Form 4 Filing
Director Jacqualyn Fouse reports acquisition of shares through restricted stock unit vesting and subsequent sale to cover tax obligations.
Summary
- On April 8, 2025, Jacqualyn A Fouse, a director of Agios Pharmaceuticals, acquired 15,933 shares of common stock through the vesting of restricted stock units.
- These restricted stock units were granted on April 8, 2022, and vest in three equal annual installments starting April 8, 2023.
- On April 10, 2025, Fouse sold 7,497 shares of common stock at a price of $25.9 per share.
- The sale was executed to cover tax withholding obligations related to the vesting of performance share units, pursuant to a pre-arranged Rule 10b5-1(c) trading plan.
- Following these transactions, Fouse directly owns 149,220 shares of Agios Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions related to vesting and tax obligations, which are routine.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to the market regarding the trading activities of company directors and officers.
Stakeholder Impact
- The transactions have a minimal impact on stakeholders as they are related to routine insider trading activities for tax purposes.
Key Dates
| Date | Description |
|---|---|
| April 8, 2022 | Date the restricted stock units were granted. |
| April 8, 2023 | Start date for the three equal annual installments of vesting shares. |
| April 8, 2025 | Date of acquisition of 15,933 shares through restricted stock unit vesting. |
| April 10, 2025 | Date of sale of 7,497 shares at $25.9 per share. |
Keywords
Agios Pharmaceuticals, Director, Stock Transactions, Form 4, Restricted Stock Units, Vesting, Rule 10b5-1(c), Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.